PriceTargets.com logo

Seagen - SGEN Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$228.74 As of 01/9/2024 01:00 AM ET
+0 (0.00%)
Get New Seagen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SGEN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SGEN

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Seagen in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $228.74.

This chart shows the closing price for SGEN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Seagen. This rating has held steady since October 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 11 hold ratings
  • 0 sell ratings
Ratings as of
6/11/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 11 hold ratings
  • 0 sell ratings
Ratings as of
9/9/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 11 hold ratings
  • 0 sell ratings
Ratings as of
12/8/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 9 hold ratings
  • 0 sell ratings
Ratings as of
3/7/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/5/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/3/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/2/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/18/2023Truist FinancialReiterated RatingHold ➝ Hold$229.00
9/25/2023Truist FinancialReiterated RatingHold ➝ Hold$229.00
8/3/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$229.00
4/28/2023Stifel NicolausBoost Target$157.00 ➝ $229.00
3/24/2023Berenberg BankDowngradeBuy ➝ Hold
3/21/2023TD SecuritiesLower TargetMarket Perform$145.00 ➝ $129.00
3/20/2023Truist FinancialBoost Target$152.00 ➝ $229.00
3/15/2023Morgan StanleyDowngradeOverweight ➝ Equal Weight$173.00 ➝ $229.00
3/14/2023BMO Capital MarketsReiterated RatingOutperform ➝ Market Perform$179.00 ➝ $229.00
3/14/2023Royal Bank of CanadaBoost TargetOutperform$155.00 ➝ $229.00
3/14/2023SVB SecuritiesBoost Target$141.00 ➝ $229.00
3/14/2023OppenheimerBoost TargetOutperform$210.00 ➝ $229.00
3/14/2023BarclaysBoost TargetEqual Weight$145.00 ➝ $228.00
3/14/2023JMP SecuritiesDowngradeOutperform ➝ Market Perform
3/13/2023Needham & Company LLCDowngradeBuy ➝ Hold
3/13/2023Raymond JamesDowngradeStrong-Buy ➝ Market Perform
3/6/2023Needham & Company LLCBoost TargetBuy$178.00 ➝ $185.00
2/28/2023GuggenheimReiterated RatingBuy$170.00
2/28/2023OppenheimerBoost TargetOutperform$180.00 ➝ $210.00
2/23/2023Needham & Company LLCBoost TargetBuy$160.00 ➝ $178.00
2/17/2023OppenheimerBoost TargetOutperform$178.00 ➝ $180.00
2/17/2023Truist FinancialBoost Target$135.00 ➝ $152.00
2/17/2023JMP SecuritiesBoost TargetMarket Outperform$142.00 ➝ $168.00
2/16/2023HC WainwrightReiterated RatingBuy$180.00
2/16/2023Needham & Company LLCReiterated RatingBuy$160.00
2/16/2023BMO Capital MarketsBoost TargetOutperform$177.00 ➝ $179.00
2/16/2023Morgan StanleyBoost TargetOverweight$170.00 ➝ $173.00
2/16/2023Royal Bank of CanadaBoost TargetOutperform$145.00 ➝ $155.00
2/16/2023Evercore ISIUpgradeIn-Line ➝ Outperform$140.00 ➝ $175.00
2/16/2023Raymond JamesUpgradeOutperform ➝ Strong-Buy$155.00 ➝ $175.00
2/13/2023JPMorgan Chase & Co.Lower TargetOverweight$154.00 ➝ $150.00
2/10/2023OppenheimerLower TargetOutperform$188.00 ➝ $178.00
2/6/2023Leerink PartnersDowngradeOutperform ➝ Market Perform$162.00 ➝ $141.00
2/6/2023SVB SecuritiesDowngradeOutperform ➝ Market Perform$162.00 ➝ $141.00
1/25/2023Berenberg BankLower TargetBuy$183.00 ➝ $170.00
1/24/2023Morgan StanleyLower TargetOverweight$171.00 ➝ $170.00
1/20/2023Leerink PartnersBoost TargetOutperform$160.00 ➝ $162.00
11/21/2022Truist FinancialInitiated CoverageHold$135.00
11/2/2022JMP SecuritiesLower TargetMarket Outperform$196.00 ➝ $142.00
11/1/2022GuggenheimLower Target$170.00
11/1/2022CowenLower Target$145.00
10/28/2022Raymond JamesLower TargetOutperform$220.00 ➝ $155.00
10/28/2022Royal Bank of CanadaLower TargetOutperform$185.00 ➝ $178.00
10/28/2022BarclaysLower TargetEqual Weight$174.00 ➝ $136.00
10/28/2022Morgan StanleyBoost TargetOverweight$170.00 ➝ $171.00
10/28/2022OppenheimerLower TargetOutperform$208.00 ➝ $188.00
10/28/2022HC WainwrightLower TargetBuy$200.00 ➝ $180.00
10/24/2022JPMorgan Chase & Co.Lower TargetOverweight$194.00 ➝ $155.00
10/13/2022Morgan StanleyLower TargetOverweight$181.00 ➝ $170.00
10/11/2022BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$177.00 ➝ $178.00
9/13/2022Leerink PartnersBoost TargetOutperform$152.00 ➝ $160.00
8/15/2022Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$179.00 ➝ $188.00
8/15/2022Leerink PartnersLower TargetOutperform ➝ Outperform$159.00 ➝ $152.00
7/29/2022Royal Bank of CanadaBoost Target$136.00 ➝ $179.00
7/29/2022Morgan StanleyBoost TargetOverweight$180.00 ➝ $181.00
7/27/2022Needham & Company LLCBoost TargetBuy$180.00 ➝ $188.00
7/27/2022HC WainwrightBoost TargetBuy$170.00 ➝ $200.00
7/19/2022GuggenheimSet Target$204.00
7/15/2022Morgan StanleyBoost TargetOverweight$173.00 ➝ $180.00
7/8/2022JMP SecuritiesBoost TargetMarket Outperform$157.00 ➝ $196.00
6/29/2022Raymond JamesInitiated CoverageOutperform$220.00
6/23/2022BMO Capital MarketsInitiated CoverageMarket Perform$169.00
6/21/2022OppenheimerBoost TargetOutperform$160.00 ➝ $208.00
6/8/2022JMP SecuritiesReiterated RatingBuy$157.00
6/6/2022Leerink PartnersBoost TargetOutperform$155.00 ➝ $159.00
5/24/2022JMP SecuritiesReiterated RatingBuy$157.00
4/18/2022JMP SecuritiesReiterated RatingBuy$157.00
4/12/2022Morgan StanleyBoost TargetOverweight$170.00 ➝ $173.00
2/16/2022JMP SecuritiesLower TargetMarket Outperform$201.00 ➝ $142.00
2/11/2022OppenheimerLower Target$198.00 ➝ $162.00
2/10/2022Stifel NicolausLower Target$180.00 ➝ $145.00
2/10/2022Wolfe ResearchLower TargetPeer Perform$195.00 ➝ $146.00
2/10/2022Bank of AmericaLower TargetBuy$210.00 ➝ $170.00
2/10/2022Royal Bank of CanadaLower TargetSector Perform$154.00 ➝ $132.00
2/10/2022Morgan StanleyLower TargetOverweight$175.00 ➝ $170.00
2/10/2022Leerink PartnersLower TargetOutperform$179.00 ➝ $155.00
2/10/2022HC WainwrightLower TargetBuy$200.00 ➝ $170.00
2/10/2022Piper SandlerLower TargetNeutral$165.00 ➝ $150.00
2/7/2022Needham & Company LLCLower TargetBuy$254.00 ➝ $200.00
1/31/2022Morgan StanleyUpgradeEqual Weight ➝ Overweight$178.00 ➝ $175.00
1/18/2022Morgan StanleyLower TargetEqual Weight$181.00 ➝ $178.00
12/14/2021JMP SecuritiesReiterated RatingBuy$201.00
11/8/2021Wolfe ResearchInitiated CoverageMarket Perform$195.00
10/29/2021Morgan StanleyBoost TargetEqual Weight$167.00 ➝ $181.00
10/29/2021OppenheimerBoost TargetOutperform$196.00 ➝ $198.00
10/28/2021Piper SandlerBoost TargetNeutral$160.00 ➝ $165.00
10/27/2021Leerink PartnersBoost TargetOutperform$190.00 ➝ $200.00
9/27/2021Royal Bank of CanadaBoost TargetSector Perform$148.00 ➝ $154.00
9/22/2021Leerink PartnersLower TargetOutperform$192.00 ➝ $190.00
9/20/2021Piper SandlerReiterated RatingHold$160.00
7/16/2021Morgan StanleyLower TargetEqual Weight$173.00 ➝ $167.00
5/17/2021Evercore ISIInitiated CoverageInline$153.00
4/30/2021Needham & Company LLCInitiated CoverageBuy$254.00
4/30/2021Piper SandlerLower TargetIn-Line ➝ Neutral$170.00 ➝ $160.00
3/30/2021Credit Suisse GroupInitiated CoverageNeutral$145.00
2/16/2021Royal Bank of CanadaLower TargetSector Perform$186.00 ➝ $169.00
2/12/2021Morgan StanleyLower TargetEqual Weight$177.00 ➝ $173.00
2/12/2021Leerink PartnersLower TargetOutperform$200.00 ➝ $192.00
2/12/2021HC WainwrightReiterated RatingBuy
2/12/2021Berenberg BankReiterated RatingBuy
2/12/2021BarclaysLower TargetEqual Weight$177.00 ➝ $168.00
2/12/2021Piper SandlerLower TargetIn-Line ➝ Neutral$175.00 ➝ $170.00
2/9/2021William BlairReiterated RatingOutperform
2/1/2021Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$188.00 ➝ $186.00
1/19/2021Morgan StanleyBoost TargetEqual Weight$175.00 ➝ $177.00
1/15/2021Bank of AmericaUpgradeNeutral ➝ Buy$215.00
11/17/2020Needham & Company LLCReiterated RatingBuy$254.00
10/30/2020Morgan StanleyBoost TargetEqual Weight$167.00 ➝ $175.00
10/30/2020Leerink PartnersLower TargetOutperform$204.00 ➝ $200.00
10/22/2020OppenheimerInitiated CoverageBuy$213.00
10/16/2020William BlairReiterated RatingBuy
10/15/2020Bank of AmericaBoost TargetNeutral$180.00 ➝ $215.00
10/13/2020JMP SecuritiesBoost TargetPositive ➝ Outperform$200.00 ➝ $216.00
10/12/2020Leerink PartnersBoost TargetOutperform$187.00 ➝ $204.00
9/22/2020JMP SecuritiesBoost Target$185.00 ➝ $200.00
9/22/2020Stifel NicolausBoost TargetHold$145.00 ➝ $165.00
9/22/2020Leerink PartnersBoost TargetOutperform$185.00 ➝ $187.00
9/18/2020Needham & Company LLCInitiated CoverageBuy$188.00
9/16/2020JPMorgan Chase & Co.Reiterated RatingBuy
9/15/2020Leerink PartnersBoost TargetOutperform$173.00 ➝ $185.00
9/15/2020Morgan StanleyBoost TargetEqual Weight$160.00 ➝ $167.00
9/14/2020Royal Bank of CanadaBoost TargetOutperform$175.00 ➝ $191.00
7/31/2020Morgan StanleyBoost TargetEqual Weight$149.00 ➝ $160.00
7/31/2020Leerink PartnersBoost TargetOutperform$167.00 ➝ $173.00
7/31/2020HC WainwrightReiterated RatingBuy$175.00 ➝ $200.00
7/24/2020Piper SandlerDowngradeOverweight ➝ Neutral$155.00 ➝ $165.00
7/2/2020William BlairReiterated RatingBuy
6/30/2020BMO Capital MarketsBoost Target$174.00 ➝ $186.00
6/30/2020Leerink PartnersBoost TargetOutperform$155.00 ➝ $167.00
6/30/2020Needham & Company LLCBoost TargetBuy$163.00 ➝ $188.00
6/26/2020OppenheimerBoost TargetPositive ➝ Outperform$175.00 ➝ $200.00
5/31/2020OppenheimerInitiated CoverageBuy$146.00 ➝ $175.00
5/26/2020JMP SecuritiesInitiated CoverageOutperform$185.00
5/26/2020The Goldman Sachs GroupUpgradeBuy ➝ Conviction-Buy
5/4/2020Morgan StanleyBoost TargetEqual Weight$111.00 ➝ $149.00
5/3/2020BarclaysReiterated RatingNeutral ➝ Hold
5/1/2020CfraBoost TargetSell$122.00 ➝ $129.00
5/1/2020Stifel NicolausBoost TargetHold$120.00 ➝ $127.00
5/1/2020Royal Bank of CanadaBoost TargetOutperform$148.00 ➝ $149.00
5/1/2020Leerink PartnersBoost TargetOutperform$146.00 ➝ $155.00
5/1/2020Needham & Company LLCBoost TargetBuy$157.00 ➝ $163.00
5/1/2020HC WainwrightBoost TargetBuy$150.00 ➝ $175.00
5/1/2020GuggenheimUpgradeNeutral ➝ Buy
4/27/2020Piper SandlerBoost TargetOverweight$135.00 ➝ $155.00
4/20/2020BMO Capital MarketsBoost TargetOutperform$139.00 ➝ $154.00
4/20/2020Leerink PartnersBoost TargetOutperform$138.00 ➝ $146.00
4/20/2020Stifel NicolausBoost TargetHold$103.00 ➝ $120.00
4/20/2020OppenheimerBoost TargetOutperform$124.00 ➝ $146.00
4/20/2020Needham & Company LLCBoost TargetPositive ➝ Buy$144.00 ➝ $157.00
4/20/2020Royal Bank of CanadaBoost TargetOutperform$121.00 ➝ $147.00
4/20/2020Piper SandlerBoost TargetOverweight$125.00 ➝ $135.00
4/19/2020Royal Bank of CanadaReiterated RatingBuy
4/15/2020Morgan StanleyBoost TargetEqual Weight$107.00 ➝ $111.00
4/3/2020William BlairReiterated RatingBuy
3/3/2020William BlairReiterated RatingOutperform
2/18/2020BarclaysDowngradeOverweight ➝ Equal Weight$124.00
2/12/2020HC WainwrightReiterated RatingBuy$140.00 ➝ $150.00
2/11/2020JPMorgan Chase & Co.Reiterated RatingBuy
2/11/2020The Goldman Sachs GroupBoost TargetBuy$126.00 ➝ $165.00
2/7/2020Piper SandlerLower Target$125.00
2/7/2020William BlairReiterated RatingOutperform
2/7/2020Needham & Company LLCReiterated RatingBuy$135.00
1/27/2020BMO Capital MarketsInitiated CoverageOutperform$139.00
1/27/2020Royal Bank of CanadaReiterated RatingBuy$113.00
1/17/2020Morgan StanleyLower TargetEqual Weight$123.00 ➝ $115.00
1/2/2020GuggenheimDowngradeBuy ➝ Neutral
12/22/2019CowenReiterated RatingHold$100.00
12/20/2019Piper Sandler CompaniesBoost TargetOverweight$120.00 ➝ $130.00
12/19/2019William BlairReiterated RatingBuy
12/19/2019Stifel NicolausBoost Target$87.00 ➝ $101.00
12/13/2019William BlairReiterated RatingBuy
12/13/2019HC WainwrightReiterated RatingBuy$140.00
12/12/2019OppenheimerBoost TargetOutperform$110.00 ➝ $124.00
12/12/2019Needham & Company LLCReiterated RatingBuy$130.00
12/10/2019Morgan StanleyInitiated CoverageEqual ➝ Equal Weight$123.00
12/3/2019Bank of AmericaInitiated CoverageNeutral$125.00
(Data available from 12/3/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/7/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/6/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/6/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/5/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/4/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/4/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/3/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/3/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Seagen logo
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.
Read More

Today's Range

Now: $228.74
Low: $228.74
High: $228.74

50 Day Range

MA: $228.74
Low: $228.74
High: $228.74

52 Week Range

Now: $228.74
Low: $123.77
High: $228.96

Volume

86 shs

Average Volume

1,478,439 shs

Market Capitalization

$42.93 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.32

Frequently Asked Questions

What sell-side analysts currently cover shares of Seagen?

The following sell-side analysts have issued reports on Seagen in the last year: StockNews.com.
View the latest analyst ratings for SGEN.

What is the current price target for Seagen?

0 Wall Street analysts have set twelve-month price targets for Seagen in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Seagen in the next year.
View the latest price targets for SGEN.

What is the current consensus analyst rating for Seagen?

Seagen currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for SGEN.

What other companies compete with Seagen?

Other companies that are similar to Seagen include Amgen, Vertex Pharmaceuticals, Gilead Sciences, Regeneron Pharmaceuticals and Alnylam Pharmaceuticals. Learn More about companies similar to Seagen.

How do I contact Seagen's investor relations team?

Seagen's physical mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The biotechnology company's listed phone number is (425) 527-4000 and its investor relations email address is [email protected]. The official website for Seagen is www.seattlegenetics.com. Learn More about contacing Seagen investor relations.